Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer

CONCLUSIONS: Alpelisib plus nab-paclitaxel combination was well-tolerated and shows encouraging efficacy, especially in patients with PIK3CA-mutated tumor/ctDNA. Impact of metabolic status on response to this combination merits further investigation.PMID:33602685 | DOI:10.1158/1078-0432.CCR-20-4879

Source: Clinical Cancer Research - February 19, 2021 Category: Cancer & Oncology Authors: Priyanka Sharma Vandana G Abramson Anne P O'Dea Lauren Nye Ingrid A Mayer Harsh B Pathak Marc Hoffmann Shane R Stecklein Manana Elia Sharon Lewis Jecinta Scott Jilliann A De Jong Yen Y Wang Rachel Yoder Kelsey Schwensen Karissa Finke Jaimie Heldstab Steph Source Type: research